ArticleBiomedicines2023

Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series.

Luigi Liguori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.